TG Therapeutics to Present at Jefferies Global Healthcare Conference

TG Therapeutics announced that CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference. Weiss will deliver a fireside chat on June 4, 2025, at 12:50 PM ET. A live webcast of the event will be available on the company's website. TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases.

TG Therapeutics Inc. (TGTX) has announced that CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference on June 4, 2025, at 12:50 PM ET. The event will feature a fireside chat with Weiss, who will discuss the company's latest advancements and the potential of BRIUMVI® (ublituximab-xiiy), a novel treatment for relapsing forms of multiple sclerosis (RMS).

The presentation comes on the heels of positive data from the ULTIMATE I & II Phase 3 trials and the ENHANCE study, which were presented at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. These trials highlighted BRIUMVI®'s safety and efficacy in treating RMS, with no association between decreased serum immunoglobulin levels and serious infections observed in long-term treatment [1]. Additionally, real-world data from the ENAMOR survey indicated favorable infusion tolerability for BRIUMVI®, and updates from the ENHANCE study confirmed the safety and tolerability of 30-minute infusions [2].

However, the data also raised concerns about infusion reactions and infections. Infusion reactions were reported in 48% of BRIUMVI-treated patients, with serious reactions in 0.6% of cases. Serious infections were slightly higher in BRIUMVI-treated patients compared to those treated with teriflunomide [1]. The drug is contraindicated in patients with active Hepatitis B Virus infection and those with a history of life-threatening infusion reactions [2].

The upcoming conference provides an opportunity for investors to gain insights into TG Therapeutics' strategic direction and the potential market impact of BRIUMVI®. Weiss's participation underscores the company's commitment to addressing unmet needs in RMS treatment and its ability to differentiate BRIUMVI® through unique glycoengineering technology [1].

References:
[1] https://www.gurufocus.com/news/2898276/tg-therapeutics-inc-tgtx-showcases-promising-briumvi-data-at-cmsc-2025-tgtx-stock-news
[2] https://www.globenewswire.com/news-release/2025/05/30/3090994/8790/en/TG-Therapeutics-Announces-Data-Presentations-for-BRIUMVI-in-Multiple-Sclerosis-at-the-2025-Consortium-of-Multiple-Sclerosis-Centers-Annual-Meeting.html